keyword
syndrom
panel
respiratori
panel
sepsi
panel
gastroenter
panel
mening
panel
enceph
panel
syndrom
panel
evolv
includ
addit
pathogen
target
syndrom
panel
flexibl
design
better
meet
user
need
syndrom
panel
includ
host
respons
marker
correl
pathogen
detect
syndrom
panel
shorter
run
time
less
complex
place
near
point
care
syndrom
panel
expand
includ
antimicrobi
resist
determin
phenotyp
suscept
result
clinic
laboratori
test
pathogen
associ
specif
syndrom
histor
reli
multipl
differ
analyt
approach
maxim
broad
pathogen
detect
especi
true
organ
cultur
feasibl
modal
instead
cultureindepend
method
antigen
detect
direct
stain
target
polymeras
chain
reaction
pcr
aggreg
convent
method
sinc
late
commerci
manufactur
vitro
diagnost
product
invest
signific
resourc
develop
disclosur
statement
mr
couturi
receiv
household
incom
biofir
diagnost
involv
clinic
trial
activ
luminex
verigen
jd
bard
consult
biofir
diagnost
acceler
diagnost
involv
clinic
trial
activ
biofir
diagnost
luminex
corpor
diasorin
molecular
arup
laboratori
univers
utah
chipeta
way
salt
lake
citi
ut
usa
b
microbiolog
virolog
laboratori
depart
patholog
laboratori
medicin
children
hospit
lo
angel
univers
southern
california
sunset
boulevard
ms
lo
angel
ca
usa
multiplex
molecular
diagnost
assay
capabl
detect
broad
array
pathogen
collect
could
caus
singl
clinic
syndrom
becam
known
syndrom
panel
approach
pathogen
test
avenu
test
design
develop
carri
recent
decad
evergrow
portfolio
offer
variou
vitro
diagnost
manufactur
syndrom
test
carri
field
clinic
microbiolog
new
frontier
diagnost
capabl
although
mani
advantag
syndrom
test
met
equal
opposit
disadvantag
challeng
common
opinion
molecular
methodolog
mani
convent
infect
accur
rapid
conveni
tradit
cultur
direct
detect
techniqu
previous
use
laboratori
next
futur
syndrom
panel
look
like
gap
unmet
need
articl
describ
current
stateoftheart
regard
commerci
avail
primari
clear
us
food
drug
administr
fda
syndrom
panel
respiratori
tract
infect
gastrointestin
gi
pathogen
detect
blood
stream
infect
central
nervou
system
cn
infect
provid
provoc
specul
look
futur
syndrom
panel
test
infecti
diseas
respiratori
tract
infect
panel
first
exampl
syndrom
test
becom
commerci
avail
clinic
laboratori
approxim
year
ago
limit
number
platform
sinc
increas
includ
multipl
differ
platform
panel
design
assay
target
upper
respiratori
tract
urt
pathogen
nasopharyng
swab
lower
respiratori
tract
pathogen
aspir
bronchial
lavag
lower
respiratori
tract
panel
tabl
recent
introduc
clinic
care
therefor
discuss
detail
owe
unclear
natur
futur
need
urt
syndrom
test
welcom
replac
insensit
cumbersom
viral
cultur
stain
well
imperfect
bacteri
serolog
assay
although
pcr
influenza
avail
laboratori
previous
syndrom
panel
expand
detect
capac
includ
broad
array
common
viral
target
select
bacteria
tradit
detect
cultur
assay
vari
term
breadth
scope
target
tabl
platform
eas
use
complex
also
variabl
extrem
end
spectrum
includ
biofir
filmarray
respiratori
ez
panel
biofir
diagnost
salt
lake
citi
ut
usa
clinic
laboratori
improv
amend
waiv
perform
near
point
care
versu
luminex
nxtag
respiratori
pathogen
panel
luminex
corpor
austin
tx
usa
high
complex
requir
molecular
laboratori
expertis
workspac
emerg
respiratori
virus
enteroviru
coronaviru
famili
member
identifi
recent
outbreak
affect
multipl
countri
emerg
evolv
virus
pose
immedi
opportun
assay
provid
comprehens
detect
respiratori
virus
filmarray
panel
current
includ
middl
east
respiratori
syndrom
coronaviru
howev
clinic
perform
fulli
understood
owe
limit
widespread
circul
viru
target
suppress
patient
meet
clinic
compat
present
open
interest
futur
opportun
flexibl
test
directfromspecimen
pathogen
identif
option
relat
pathogen
posit
predict
valu
test
result
significantli
impair
absenc
circul
viru
emerg
respiratori
pathogen
eg
middl
east
respiratori
syndrom
coronaviru
enteroviru
sever
acut
respiratori
syndrom
could
includ
syndrom
panel
endus
could
option
disabl
target
absenc
document
circul
altern
approach
could
certain
target
could
test
immedi
visibl
result
could
instead
commun
manufactur
cloudbas
surveil
system
way
sporad
fals
posit
could
easili
identifi
communitylevel
cluster
posit
could
identifi
manufactur
investig
commun
endus
laboratori
treat
physician
could
ensu
although
may
orwellian
intrus
system
similar
voluntari
surveil
system
alreadi
exist
biofir
user
could
valu
futur
epidemiolog
outbreak
identif
rather
continu
chase
outbreak
fact
earlier
crowd
share
silent
surveil
data
could
serv
entir
commun
sound
alarm
sporad
falseposit
result
process
would
requir
discuss
pay
extra
effort
target
detectionmanufactur
public
health
endus
simpl
rapid
near
pointofcar
test
futur
urt
pathogen
test
ultim
come
near
pointofcar
extrem
rapid
turn
around
time
although
microbiolog
laboratori
hesit
let
go
test
fiefdom
logic
progress
test
rapid
decis
make
lie
answer
immedi
avail
action
exampl
technolog
bring
singl
respiratori
pathogen
test
near
point
care
influenza
embrac
mani
health
care
set
despit
imperfect
perform
characterist
allow
effici
use
emerg
room
decreas
cost
comprehens
urt
panel
even
shorter
turn
around
time
current
assay
could
allow
improv
manag
admiss
patient
cohort
possibl
reduc
earli
empir
often
unnecessari
antibiot
administr
gi
pathogen
detect
histor
reli
upon
multipl
classic
complementari
diagnost
modal
eg
cultur
fecal
antigen
detect
microscopi
singl
target
pcr
creat
comprehens
pseudopanel
target
longstand
challeng
respect
gi
pathogen
detect
includ
multipl
factor
limit
capac
local
laboratori
lack
use
refer
laboratori
test
acut
gi
ill
physician
order
laps
stem
lack
understand
test
method
detect
capabl
preanalyt
analyt
factor
decreas
sensit
avail
method
eg
delay
transport
preserv
stool
inexperienc
technologist
gener
unfamiliar
less
frequent
encount
pathogen
syndrom
panel
approach
challeng
compartment
pathogen
singl
larg
panel
multipl
modular
panel
group
taxonom
related
eg
bacteria
virus
protozoa
small
modular
panel
detect
common
bacteria
virus
protozoa
panel
part
target
highest
preval
signific
organ
expens
less
comprehens
detect
pathogen
panel
capabl
detect
salmonella
shigella
campylobact
jejunicoli
shigalik
toxin
gene
shigatoxigen
escherichia
coli
essenti
replac
convent
stool
cultur
howev
clinic
concern
fail
detect
less
frequent
encount
pathogen
vibrio
yersinia
entrocolitica
enterotoxigen
e
coli
drove
creation
expand
bacteri
panel
could
consid
specif
patient
popul
patient
initi
test
neg
common
bacteri
pathogen
tabl
similarli
standalon
parasit
panel
primarili
target
common
protozo
pathogen
view
replac
stool
ova
parasit
examin
rare
subset
patient
requir
full
ova
parasit
examin
rule
helminth
infect
less
common
protozo
pathogen
eg
cystoisospora
balantioid
common
configur
test
includ
giardia
cryptosporidium
entamoeba
histolytica
see
tabl
modular
panel
enter
viral
pathogen
wide
commerci
date
product
bd
beckton
dickinson
franklin
lake
nj
usa
clearanc
fda
see
tabl
may
understand
practic
standpoint
convent
test
gi
virus
univers
embrac
standard
care
except
rotaviru
antigen
detect
neonat
pcr
norovirus
outbreak
set
sever
commerci
panel
capabl
detect
bacteria
virus
protozoa
singl
assay
tabl
panel
vari
specif
target
case
bacteria
virus
howev
core
set
pathogen
target
includ
commerci
assay
target
thought
repres
common
enter
pathogen
target
unclear
unestablish
signific
date
gi
panel
includ
definit
pathogen
howev
detect
organ
less
definit
establish
pathogen
target
includ
enteroaggreg
e
coli
enteropathogen
e
coli
plesiomona
shigelloid
manufactur
consid
remov
masqu
target
conduct
addit
clinic
studi
better
establish
signific
specif
test
popul
integr
panel
glare
hole
design
commerci
assay
notabl
exclus
cyclospora
cayetanensi
pathogen
signific
import
america
recent
decad
becom
quasiseason
ill
unit
state
owe
import
produc
serv
vehicl
multist
nationwid
outbreak
one
studi
alreadi
demonstr
valu
detect
c
cayetanensi
directli
stool
specimen
outbreak
despit
preval
clinicalepidemiolog
signific
target
exclud
multipl
panel
favor
e
histolytica
see
tabl
although
e
histolytica
virul
protozo
pathogen
incid
low
develop
countri
author
laboratori
cyclospora
frequent
detect
protozo
pathogen
e
histolytica
rank
fifth
protozoa
detect
syndrom
panel
furthermor
commerci
assay
abl
specif
identifi
e
histolytica
nonpathogen
entamoeba
dispar
limit
essenti
problem
plagu
ova
parasit
examin
centuri
improv
specieslevel
specif
e
histolytica
inclus
cyclospora
futur
product
imper
test
c
difficil
area
clinic
diagnosi
evolv
significantli
past
decad
although
nuanc
opinion
regard
infect
beyond
scope
work
practic
issu
aris
result
panel
test
includ
target
test
c
difficil
children
less
month
age
tradit
discourag
children
age
group
often
asymptomat
colon
furthermor
test
c
difficil
otherwis
healthi
adult
popul
without
previou
use
antibiot
hospit
hospit
exposur
histor
advoc
primari
clinic
evalu
inclus
target
increas
risk
overdiagnosi
c
difficil
anoth
futur
area
consider
aid
interpret
colon
versu
infecti
state
could
includ
integr
mucos
inflammatori
marker
express
exampl
proinflammatori
cytokin
marker
acut
inflamm
could
serv
adjunct
metric
aid
interpret
detect
potenti
colon
like
c
difficil
organ
capabl
shed
week
month
convalesc
eg
salmonella
noroviru
would
area
still
need
signific
research
molecular
profil
inflammatori
bowel
diseas
similar
condit
yet
standard
care
demograph
regionspecif
assay
conveni
endus
custom
area
futur
consider
manufactur
futur
gi
syndrom
test
must
customiz
fit
need
individu
laboratori
region
overtest
target
low
preval
region
demograph
exampl
although
includ
cyclospora
syndrom
panel
may
relev
america
tropicalsubtrop
countri
may
complet
unnecessari
target
region
eg
canada
northern
eastern
europ
although
rare
infect
may
encount
region
may
cost
effect
test
specimen
target
absenc
true
infect
posit
predict
valu
target
poor
consid
demographicdriven
test
commun
hospit
primarili
uncompl
patient
would
differ
pathogen
list
consid
clinic
care
larg
academ
medic
center
support
transplant
center
human
immunodefici
viru
clinic
traveltrop
medicin
clinic
flexibl
endus
design
alreadi
exist
verigen
luminex
corp
austin
tx
usa
rp
flex
assay
one
challeng
unmet
current
gi
syndrom
test
detect
antimicrobi
resist
primari
empir
antibiot
daunt
technic
challeng
specimen
stool
contain
copiou
genera
commens
microbiota
howev
even
target
primari
resist
could
invalu
clinic
care
enter
bacteri
pathogen
organ
shigella
salmonella
campylobact
current
cultur
syndrom
test
effort
maintain
public
health
outbreak
track
also
provid
primari
antimicrobi
suscept
test
select
drug
class
case
sever
infect
organ
often
cultur
primari
syndrom
test
marker
macrolid
quinolon
andor
tetracyclin
resist
could
extrem
help
treat
clinician
epidemiolog
report
clearli
technic
challeng
request
one
may
idealist
realist
given
current
technolog
nonetheless
futur
target
goal
test
futur
syndrom
test
gi
pathogen
consid
customiz
regionaldemographicdriven
target
inclus
clinic
relev
target
wellestablish
clinic
signific
inclus
inflammatori
marker
aid
identifi
potenti
colon
versu
activ
infect
inclus
antimicrobi
resist
determin
outbreak
associ
bacteri
pathogen
expediti
identif
bloodstream
pathogen
use
molecular
syndrom
panel
dramat
alter
standard
care
mani
laboratori
current
fdaclear
multiplex
assay
directli
posit
blood
cultur
tabl
bacteri
panel
coupl
resist
determin
fungal
panel
panel
gener
minimum
inhibitori
concentr
lieu
resist
marker
current
direct
whole
blood
panel
expans
exist
panel
includ
addit
pathogen
comprehens
resist
determin
ongo
eplex
bcidgp
panel
current
comprehens
panel
gramposit
organ
also
includ
pangramneg
pancandida
target
safeguard
gram
stain
interpret
see
tabl
addit
gramposit
organ
may
consid
streptococcu
mitisorali
import
bloodstream
infect
bsi
agent
patient
underli
hematolog
oncolog
diseas
corynebacterium
jeikeium
inclus
target
mycobacterium
speci
particularli
rapidgrow
nontuberculosi
mycobacterium
would
also
benefici
certain
patient
demograph
rel
underappreci
pathogen
group
anaerob
account
approxim
bsi
come
gramneg
panel
bcidgn
target
numer
oblig
anaerob
includ
fusobacterium
necrophorum
f
nucleatum
bacteriod
fragili
likewis
next
gener
filmarray
bcid
includ
b
fragili
inclus
addit
oblig
anaerob
eg
clostridium
spp
would
expand
breadth
coverag
offer
syndrom
panel
inclus
select
agent
target
brucella
spp
franciscella
spp
burkholderia
pseudomallei
may
prevent
unnecessari
laboratori
exposur
request
may
oner
manufactur
fulfil
owe
restrict
associ
select
agent
test
last
develop
fungal
panel
includ
comprehens
list
mold
would
significantli
improv
time
identif
eplex
bcidfp
panel
offer
detect
fusarium
spp
see
tabl
addit
relev
target
consid
scedosporium
apiospermum
lomentospora
prolifican
crucial
unmet
need
bypass
primari
incub
step
entir
excit
new
technolog
current
develop
excel
summari
technolog
provid
sinha
colleagu
first
innov
step
holi
grail
approach
releas
fdaclear
whole
blood
assay
see
tabl
target
bacteria
candida
speci
signific
mileston
bsi
diagnost
provid
insight
futur
panel
starter
whole
blood
syndrom
test
adjunct
convent
blood
cultur
manufactur
must
consid
pediatr
popul
associ
blood
volum
limit
requir
less
ml
blood
children
would
optim
second
target
incorpor
must
analog
aforement
direct
posit
blood
cultur
panel
prefer
compendi
list
bacteri
viral
fungal
pathogen
offer
without
compromis
sensit
test
abil
detect
polymicrobi
infect
despit
low
pathogen
load
paramount
appropri
antimicrobi
coverag
importantli
breadth
target
high
sensit
allow
high
confid
neg
result
potenti
decreas
antimicrobi
use
overarch
goal
target
agnost
possibl
maintain
rapid
number
caveat
whole
blood
syndrom
test
need
rectifi
widespread
adopt
first
increas
risk
contamin
exist
particularli
extens
manual
manipul
requir
emerg
technolog
attempt
allevi
risk
innov
approach
includ
use
small
reaction
mixtur
volum
reduc
number
contamin
dna
second
current
bsi
syndrom
panel
price
conduc
test
patient
correspond
blood
cultur
manufactur
must
awar
budgetari
limit
instil
laboratori
may
prohibit
adopt
develop
diagnost
algorithm
integr
host
respons
predic
whole
blood
syndrom
test
may
potenti
strategi
distinguish
low
risk
patient
septic
patient
septicyt
immunexpress
inc
seattl
wa
recent
fdaclear
quantit
revers
transcriptas
pcr
base
assay
measur
level
biomark
distinguish
sepsi
noninfecti
process
adult
patient
pilot
studi
pediatr
patient
also
demonstr
promis
result
noteworthi
limit
requir
ml
test
futur
develop
host
respons
assay
also
cogniz
blood
volum
constraint
inargu
impact
time
suscept
result
profound
allow
antimicrobi
optim
new
gener
bsi
syndrom
panel
current
develop
expand
list
resist
target
epidemiolog
therapeut
import
includ
mecc
gene
howev
target
detect
extendedspectrum
betalactamas
product
remain
limit
bla
ctxm
gene
would
benefit
addit
gene
includ
bla
shv
bla
tem
contrast
genotyp
resist
detect
offer
major
panel
pauciti
rapid
phenotyp
suscept
platform
although
test
modal
clinic
use
panel
provid
simultan
identif
phenotyp
suscept
result
function
standalon
test
expans
identif
capabl
exist
phenotest
bc
acceler
diagnost
tucson
az
usa
would
benefici
gramposit
target
current
limit
see
tabl
manufactur
need
also
cogniz
priorit
releas
suscept
test
option
novel
antimicrobi
agent
accommod
clinic
breakpoint
chang
final
amalgam
direct
whole
blood
syndrom
panel
phenotyp
suscept
test
ambiti
request
may
realist
fulfil
near
year
laboratori
diagnost
test
compulsori
confirm
cn
infect
diagnost
accuraci
convent
microbiolog
approach
gram
stain
cultur
hamper
low
sensit
andor
slow
turnaround
time
new
emerg
diagnost
approach
aid
diagnosi
mening
enceph
may
address
limit
current
laboratori
practic
current
fdaclear
test
detect
pathogen
directli
cerebrospin
fluid
csf
specimen
tabl
first
limitedtarget
key
point
current
syndrom
test
cn
infect
includ
increas
pathogen
detect
compar
convent
laboratori
approach
associ
risk
contamin
necessit
need
strict
adher
molecular
test
polici
low
viral
load
csf
certain
virus
eg
herp
simplex
viru
may
warrant
addit
test
altern
sourc
eg
blood
molecular
test
may
suboptim
certain
pathogen
eg
cryptococc
antigen
test
continu
diagnost
standard
detect
herp
virus
could
repres
either
latent
activ
infect
chromosom
integr
also
possibl
patient
posit
human
herp
inherit
chromosom
integr
human
herp
corrobor
find
clinic
pictur
paramount
ensur
appropri
diagnosi
patient
manag
syndrom
test
cn
infect
remain
infanc
continu
innov
develop
fundament
diagnost
advanc
cn
infect
quick
fix
current
futur
manufactur
may
consid
would
decreas
requir
csf
volum
accommod
copiou
number
test
often
order
may
valuabl
offer
customiz
panel
acut
versu
chronic
cn
infect
acut
mening
often
caus
virus
bacteria
includ
filmarray
meningitisenceph
panel
contrast
chronic
mening
result
infect
mycobacterium
tuberculosi
fungal
pathogen
includ
aspergillu
histoplasma
blastomyc
coccidiod
inclus
addit
uncultiv
pathogen
may
add
valu
panel
eg
bartonella
spp
treponema
pallidum
demograph
consider
expand
geograph
includ
pathogen
may
applic
certain
region
entir
nich
cn
infect
remain
untouch
cumul
incid
rate
shunt
infect
rang
per
patient
infect
occur
within
day
surgeri
commerci
molecular
test
exist
diagnosi
shunt
infect
microbiolog
cultur
remain
primari
approach
microbiolog
demograph
shunt
infect
attribut
skin
flora
differ
significantli
patient
acut
mening
enceph
filmarray
mening
enceph
panel
appropri
patient
indwel
devic
also
approv
fda
test
laboratorydevelop
molecular
test
detect
staphylococcu
aureu
cutibacterium
acn
shunt
specimen
yield
promis
data
includ
increas
detect
patient
prior
antimicrobi
exposur
envis
futur
assay
target
common
shunt
pathogen
includ
aureu
c
acn
coagulaseneg
staphylococci
gramneg
organ
candida
spp
foreseen
limit
would
risk
skin
flora
contamin
may
imped
inclus
coagulaseneg
staphylococci
target
arboviru
infect
import
caus
neuroinvas
diseas
associ
endem
transmiss
travelrel
mosquito
exposur
molecular
test
csf
specimen
may
inferior
case
arboviru
infect
window
viral
detect
mere
day
symptom
onset
compar
measur
igm
igg
antibodi
respons
remain
elev
week
thu
diagnosi
made
primarili
serolog
howev
superior
serolog
test
may
hamper
immunosuppress
patient
stress
need
enhanc
diagnost
tool
recent
studi
reveal
promis
result
detect
west
nile
viru
whole
blood
urin
retrospect
studi
patient
west
nile
viru
confirm
superior
molecular
detect
west
nile
viru
whole
blood
compar
csf
sensit
respect
yet
molecular
test
csf
specimen
may
still
valuabl
potenti
syndrom
panel
routin
detect
arbovirus
may
integr
molecular
test
whole
blood
csf
alongsid
serolog
test
improv
diagnost
yield
owe
activ
innat
immun
system
cn
rapidli
respond
alter
cn
homeostasi
level
biomark
cytokin
releas
csf
may
diagnost
discrimin
futur
syndrom
panel
may
incorpor
molecular
target
detect
alongsid
marker
host
respons
studi
role
biomark
predict
cn
infect
differenti
bacteri
viral
mening
ongo
csf
lactat
may
promis
marker
rule
bacteri
mening
high
sensit
specif
albeit
signific
decreas
sensit
note
antibiot
exposur
recent
proofofconcept
studi
use
luminex
flexmpa
technolog
determin
quantif
cytokin
level
csf
rule
infecti
process
specif
high
level
present
cn
infect
level
significantli
higher
nonvir
infect
deciph
oncolog
process
autoimmun
enceph
may
also
possibl
indic
high
level
glioma
potenti
steward
diagnost
test
would
includ
screen
infecti
process
cytokin
profil
follow
subsequ
test
syndrom
panel
method
could
potenti
provid
deciph
latent
versu
activ
viral
infect
case
chromosom
integr
human
herp
integr
algorithm
approach
must
maintain
stat
test
capabl
maxim
benefit
expediti
test
current
offer
syndrom
panel
extens
research
requir
determin
true
clinic
perform
use
test
inclus
potenti
resist
marker
andor
direct
specimen
phenotyp
suscept
may
benefici
cn
pathogen
includ
streptococcu
pneumonia
haemophilu
influenza
e
coli
one
exampl
establish
h
influenza
antimicrobi
profil
betalactamas
posit
betalactamas
neg
ampicillin
suscept
betalactamas
posit
ampicillin
resist
detect
gene
line
potenti
assay
shunt
infect
inclus
meca
mecc
gene
detect
methicillin
resist
aureu
benefici
idealist
request
develop
direct
posit
csf
specimen
phenotyp
suscept
test
futur
develop
may
consid
either
standalon
identif
suscept
test
platform
collabor
exist
identif
platform
consolid
suscept
portion
numer
area
opportun
advanc
role
syndrom
panel
clinic
care
respiratori
gi
blood
stream
infect
cn
base
primari
point
articl
futur
syndrom
test
includ
refin
exist
target
inclus
emerg
pathogen
target
expans
specimen
type
volum
requir
test
integr
host
respons
marker
inclus
addit
antimicrobi
resist
determin
phenotyp
suscept
simpl
fast
near
pointofcar
platform
